iRadimed

iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.

Small Cap

CDNA

IRMD

OMCL

TCMD

TDOC

TSX:WELL

The healthcare technology sector is undergoing a transformation, with companies leveraging AI, telemedicine, and digital platforms to innovate the way care is delivered. As demand for more efficient and patient-centric solutions grows, several public companies have emerged as leaders in this space. 

1. Teladoc Health

Market Cap: $1.4 Billion

Future Forward: 7 Groundbreaking Healthcare Technology Companies Poised To Disrupt the Industry By 2025

News

Short Ideas

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

NTAP

The Nasdaq 100 closed lower by more than 50 points on Thursday. Investors, meanwhile, focused on some notable insider trades.

Caleres, Cloudflare And 2 Other Stocks Insiders Are Selling

Health Care

General

Iradimed Notifies Potential Issue With Certain Syringe Adapter Sets During Use

iRadimed Corp

Press Releases

IRADIMED CORPORATION Named to Fortune's 100 Fastest Growing Companies List for 2024

IRADIMED CORPORATION on Forbes' List of America's Most Successful Small-Cap Companies for 2025

IRADIMED CORPORATION to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Earnings

IRADIMED CORPORATION Reports Preliminary Unaudited Record Fourth Quarter and Full-Year 2024 Revenues

IRADIMED CORPORATION to Hold Fourth Quarter of 2024, Full Year of 2024 Financial Results Conference Call on February 13, 2025

IRADIMED CORPORATION Announces Fourth Quarter and Full Year of 2024 Financial Results and Increases its Regular Quarterly Cash Dividend to $0.17 Per Share from $0.15 Per Share

IRADIMED CORPORATION To Participate at the 37th Annual Roth Conference

IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025

CORRECTION -- IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025

IRADIMED CORPORATION Announces First Quarter 2025 Financial Results

AngioDynamics

Artivion

AtriCure

Axogen

Beta Bionics

Butterfly Network, Inc. Class A Common Stock

Butterfly Network

CeriBell

ClearPoint Neuro

Conmed

Delcath Systems

Enovis

Integra LifeSciences Holdings Corporation - Common Stock

Integra Lifesciences

Kestra Medical Technologies, Ltd. - Common Stock

Kestra Medical Techs

LeMaitre Vascular

NeuroPace

Orthofix Medical

Omnicell

Pulse Biosciences

Senseonics Holdings

SI-BONE

Semler Scientific

Surmodics

SS Innovations International Inc. - Common Stock

SS Innovations

Treace Medical Concepts, Inc. - Common Stock

Treace Medical Concepts

Tandem Diabetes Care, Inc. - Common Stock

Tandem Diabetes Care

Roth MKM

Comments

iRadimed

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell